Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).

“People are scared to discuss these things,” Nelson said. “However, seeking medical advice is crucial for proper diagnosis ...

Nausea. Severe abdominal pain. Compulsive bathing. These are some of the hallmarks of cannabinoid hyperemesis syndrome, a ...

The latest data from WHO show that tuberculosis remains a formidable global health concern, with an estimated 10·8 million ...